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Abstract: Hepatocellular carcinoma (HCC) is a leading cause of new cancer diagnoses in the
United States, with an incidence that is expected to rise. The etiology of HCC is varied and can
lead to differences between patients in terms of presentation and natural history. Subsequently,
physicians treating these patients need to consider a variety of disease and patient characteristics
when they select from the many different treatment options that are available for these patients.
At the same time, the treatment landscape for patients with HCC, particularly those with
unresectable HCC, has been rapidly evolving as new, evidence-based options become available.
The treatment plan for patients with HCC can include surgery, transplant, ablation, transarterial
chemoembolization, transarterial radioembolization, radiation therapy, and/or systemic therapies.
Implementing these different modalities, where the optimal sequence and/or combination has not been
defined, requires coordination between physicians with different specialties, including interventional
radiologists, hepatologists, and surgical and medical oncologists. As such, the implementation of a
multidisciplinary team is necessary to develop a comprehensive care plan for patients, especially
those with unresectable HCC.
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1. Introduction
Cancers of the liver and bile duct, of which hepatocellular carcinoma (HCC) is the most common
type, are expected to be the 13th leading cause of new cancer diagnoses in men in the United States
in 2019 [1]. An estimated 31,780 deaths due to these cancers are anticipated, making them the fifth
leading cause of cancer-related mortality in men and seventh leading cause in women [2]. Unlike
many other common cancer types, incidence of HCC is expected to continue to rise, with a similar
increase in the rate of deaths due to HCC.
The etiology of HCC is varied, with a range of different presentations and natural histories [3].
Approximately 85% of patients diagnosed with HCC have cirrhosis of the liver, although patients
infected with the hepatitis B virus (HBV) or with aflatoxin B1 exposure may develop HCC without
underlying cirrhosis, which is rarely the case for patients infected with the hepatitis C virus (HCV).
Non-alcoholic steatohepatitis, also known as fatty liver disease, is another common cause of cirrhosis
that can progress to HCC. Development of hepatic malignancy has also been linked to alcohol use and
the presence of certain genetic mutations.
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At the level of the individual patient, concomitant cirrhosis and the number, size, and location of
hepatocellular tumors will affect the treatment approach. In addition, multiple disease-related factors
need to be taken into account, such as the presence of vascular involvement or extrahepatic disease,
when deciding on the best treatment options for these patients. Consequently, a multidisciplinary
approach involving several physicians with different specialties (e.g., diagnostic and interventional
radiologists, surgical oncologists, hepatologists, and medical oncologists) is necessary to determine the
best approach to treatment and maximize potential outcomes for patients with HCC.
2. The Evolving Treatment Paradigm for Patients with Unresectable HCC
Surgery or liver transplant are preferred options for patients with HCC as they can be curative,
but approximately 70% of patients are diagnosed at a stage that prohibits these treatments [4–8].
Transplant may become an option for down-staging therapy as a bridge to permit some patients
who could not initially undergo transplant to eventually become transplant candidates if they have
durable responses with a reduction in number or size of tumors to within acceptable criteria. Multiple
guidelines have been created to address the treatment of patients with HCC who cannot undergo
resection or transplant (Table 1). Many different treatment modalities have been endorsed in these
guidelines, with treatment selection based upon both patient and disease characteristics. Consequently,
a multidisciplinary approach is necessary to ensure that the guidelines are adhered to and patients are
treated with the right modalities at the right time.
2.1. Locoregional Therapy
Locoregional treatments are a set of therapeutic approaches that directly target tumors in the
liver. Among the locoregional modalities, ablative therapies are commonly used for tumors that can be
accessed without damaging surrounding structures [6]. Outcomes for patients with tumors <2 cm
who undergo ablation are generally similar to those having surgery [4].
Transarterial chemoembolization (TACE) is another locoregional modality that involves the local
delivery of chemotherapy to the tumor and is generally recommended for patients with liver-limited
disease [4–8]. Several randomized trials have been conducted to examine the efficacy and safety of
TACE. In one notable study, patients with untreated hepatocellular tumors who were not suitable
for curative treatments and who had Child–Pugh A or B liver function were randomized to arterial
embolization, TACE, or symptomatic treatment (N = 112) [9]. Results showed that the probability of
survival at 1, 2, and 3 years was highest for the TACE group. In addition, median overall survival (OS)
was significantly longer in the TACE group relative to the symptomatic treatment group (25.3 months
vs. 17.9 months, p = 0.009; comparison to the embolization group was not made because the trial was
stopped early). A similar study was conducted in 79 Asian patients with newly diagnosed HCC where
the estimated 1-, 2-, and 3-year survival rates were 57%, 31%, and 26%, respectively, in the TACE group,
compared with 32%, 11%, and 3%, respectively, for the symptomatic treatment control group [10]. The
relative risk of death was significantly lower in the TACE group (RR 0.50 [95% CI 0.31–0.81; p = 0.005).
These results showed important survival benefits of the procedure, but it is important to keep in
mind that prognosis after TACE in virtually all patients is eventually limited by progression of liver
disease or cancer. Consequently, TACE failure has been defined in several different ways, including
lack of substantial necrosis by mRECIST criteria after two rounds, failure of follow-up treatment
to induce necrosis in progressing sites, major progression (defined as substantial liver involvement,
vascular invasion, and/or extrahepatic spread) after an initial response, deterioration to Child–Pugh
C liver function, or poor tolerance. Unfortunately, no uniform consensus exists on the definition of
“TACE failure” [4,6].
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Table 1. Recommendations from selected guidelines for the treatment of patients with unresectable HCC.
AASLD/ESMO-EORTC [4,7] NCCN [6] HKLC [8]
Definition of
unresectable
disease
• In patients with Child–Pugh A-B liver
function and ECOG PS 0
- Single nodule in a patient with
increased bilirubin
- 3 nodules ≤3 cm
• Multinodular disease
• Portal vein invasion
• Extrahepatic spread
• ECOG PS 1–4
• Inadequate liver function (i.e., Child–Pugh B or higher
or Child–Pugh A with portal hypertension)
• Multiple masses
• Vascular invasion
• Inadequate future liver remnant after surgery
• In patients with no extrahepatic vascular
invasion/metastases
- Intermediate tumor a with Child–Pugh B
liver function, ECOG PS 0–1
- Locally advanced tumor b with Child–Pugh
A-B liver function and ECOG PS 0–1
• Patients with extrahepatic vascular
invasion/metastases and Child–Pugh A-B
liver function
• Patients with ECOG PS 2-4 and Child–Pugh C
liver function
Recommendations
for LRT
• Ablation
- Single nodule ≤2 cm, Child–Pugh
A liver function, and ECOG PS 0 in
patients who are not candidates
for transplant
- Single nodule or three nodules ≤3
cm, Child–Pugh A–B, ECOG PS 0,
increased portal vein pressure, and
associated disease
• TACE: multinodular disease,
Child–Pugh A-B, ECOG PS 0
• TARE: not eligible for TACE
or sorafenib
• Consider for patients who are not candidates for surgery
or as part of a bridge strategy for other
curative therapies
• Ablation
- The tumor and a surrounding margin of tissue can be
treated (i.e., tumors ≤5 cm)
- Accessible location without damaging major vessels
or bile ducts, the diaphragm, or other organs
• TACE
- Arterial blood supply to tumor can be isolated
- Bilirubin ≤3 mg/dL, no PVT, Child–Pugh A or B
• TARE
- Arterial blood supply to tumor can be isolated
- Bilirubin ≤2 mg/dL, no PVT, Child–Pugh A or B
• EBRT
- All tumors irrespective of location in patients with
unresectable disease
- Consider as an alternative to ablation, TACE, or TARE
- May be appropriate for symptom control and/or
prevention of complications from metastatic disease
• Ablation
- Early tumor c, no extrahepatic vascular
invasion/metastases, ECOG Ps 0–1,
Child–Pugh A-B liver function
• TACE
- Intermediate tumor, no extrahepatic
vascular invasion/metastases, Child–Pugh B
liver function, ECOG PS 0–1
- Locally advanced tumor, no extrahepatic
vascular invasion/metastases
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Table 1. Cont.
AASLD/ESMO-EORTC [4,7] NCCN [6] HKLC [8]
Recommendations
for systemic
treatment
• Patients with portal vein invasion,
extrahepatic spread, Child–Pugh A-B,
ECOG PS 1–2
• Not a candidate for curative or
locoregional treatments due to
stage migration
• Sorafenib
- Child–Pugh A (category 1) or B (category 2A)
liver function
- Extensive disease; patient not suitable for transplant
- Not suitable for resection due to comorbidity or
presence of metastases
• Lenvatinib
- Child–Pugh A liver function
• Regorafenib
- Child–Pugh A liver function
- Progression on sorafenib
• Cabozantinib
- Child–Pugh A liver function
- Progression on sorafenib
• Nivolumab
- Child–Pugh A or B7 liver function
- Progression on sorafenib
• Pembrolizumab
- Child–Pugh A liver function
- Progression on sorafenib
• Ramucirumab
- AFP ≥ 400 ng/mL
- Progression on sorafenib
• Extrahepatic vascular invasion/metastases
• Child–Pugh A-B liver function, ECOG PS 0–1
Recommendations
for palliative care
• Child–Pugh C, ECOG PS 3–4
• Extensive tumor
• Advanced liver disease
• EBRT may be appropriate for symptom control and/or
prevention of complications from metastatic disease
• Should be offered to patients with unresectable disease,
metastatic disease, or extensive tumor burden
• Extrahepatic vascular invasion/metastases
• ECOG PS 2–4, Child–Pugh C liver function
AASLD, American Association for the Study of Liver Disease; EBRT, external beam radiation; ECOG PS, Eastern Cooperative Oncology Group performance status; ESMO-EORTC,
European Society for Medical Oncology-European Organization for Research and Treatment of Cancer; HKLC, Hong Kong Liver Cancer; LRT, locoregional treatment; NCCN, National
Comprehensive Cancer Networks; PVT, portal vein thrombosis; TACE, transarterial chemoembolization; TARE, transarterial radioembolization. a Intermediate tumor = ≤5 cm, >3 nodules,
and no intrahepatic venous invasion or >5 cm, ≤3 nodules with intrahepatic venous invasion. b Locally advanced tumor = ≤5 cm, >3 nodules with intrahepatic venous invasion, or >5 cm,
>3 tumor nodules or/and with intrahepatic venous invasion, or diffuse tumor. c Early tumor = ≤5 cm, ≤3 tumor nodules and no intrahepatic venous invasion.
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Transarterial radioembolization (TARE) is another locoregional therapy option for patients with
liver-dominant disease in which microspheres laden with yttrium-90 (Y-90) are used to deliver radiation.
Two types of Y-90–laden microspheres are available in the United States: resin spheres (SIR-Spheres®;
Sirtex Medical Limited; North Sydney, Australia) in which the microspheres are coated with Y-90,
and glass spheres (TheraSphere®; BTG International Medicine; London, UK) in which the isotope is
an intrinsic component of the microsphere. Recent data showed no improvements in survival but
superior local tumor control through TARE with Y-90 resin microspheres relative to systemic therapy
with sorafenib (NEXAVAR®; Bayer, Whippany, NJ, USA) in heavily pretreated patients with liver-only
disease [11,12]. Although TARE was better tolerated, hazard ratios for OS (which were similar in
both trials and trended toward better survival with sorafenib) showed no evidence of superiority
to sorafenib in terms of OS; however, the design of the trial may have contributed to this finding.
Specifically, the inclusion of patients who had already progressed on ≥2 rounds of TACE essentially
selected for patients who had already failed locoregional therapy. Prior TACE may have also increased
the likelihood that patients had vascular occlusion, which would have limited the effectiveness of
subsequent TARE. Several patients randomized to TARE did not get the intended therapy because
they lacked access to a site that could perform the procedure in Asia, which confounded the analysis of
the intent-to-treat sample.
2.2. Radiation Therapy
External beam radiation therapy (EBRT) may also be considered for locoregional treatment
of hepatocellular tumors. Guidelines from the National Comprehensive Cancer Network (NCCN)
recommend that EBRT be considered for all unresectable tumors [6]. EBRT may also be useful for
symptom control in patients with metastatic disease [6], although this remains controversial. Additional
data are needed to further clarify the role of EBRT in the treatment of patients with unresectable HCC.
2.3. Systemic Therapy
Systemic therapy has traditionally been thought of as an option for patients who are not suitable
for locoregional therapies or who have extensive intra- or extrahepatic disease [4–8]. This largely
confines this modality to BCLC STAGE C patients. As of the time of writing of this review, there are
now six FDA-approved systemic therapies for unresectable HCC, up from only sorafenib merely three
years ago. These include sorafenib and lenvatinib in front line as well as regorafenib, nivolumab,
pembrolizumab, ramucirumab and cabozantinib in persons previously treated with sorafenib. Survival
data for persons treated with multiple lines of therapy are emerging. The following is a critical
appraisal of the evidence that led to these approvals and a perspective on where they fit in the current
treatment arsenal of unresectable HCC.
2.4. Front-Line Therapies
For the last 12 years, sorafenib has been the mainstay of systemic treatment for patients with
HCC based on the results of 2 randomized phase 3 clinical trials. The SHARP trial primarily enrolled
patients from Europe and North/Central/South America with advanced-stage (Barcelona Clinic Liver
Cancer [BCLC] stage C) disease and Child–Pugh A liver function, and ECOG PS ≤2 who were not
eligible for surgical or locoregional therapy [13]. The results showed that median OS was 10.7 months
in the sorafenib-treated group, compared with 7.9 months in the placebo-treated group (HR 0.69 [95%
CI 0.55 to 0.87], p < 0.001).
Lenvatinib (LENVIMA®; Eisai, Inc.; Woodcliff Lake, NJ, USA) is a tyrosine kinase inhibitor that
primarily targets VEGFR-1,2,3, as well as FGF and other pathways that have been implicated in tumor
angiogenesis and proliferation, including RET, KIT, and PDGFRα [14]. The REFLECT trial was a
randomized, open-label trial comparing lenvatinib with sorafenib in patients with unresectable HCC
who had not previously been treated with systemic therapy. While the majority of enrolled patients
had BCLC C disease, the trial excluded potential patients with tumor burden exceeding 50% of total
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liver volume, tumor invasion of a large bile duct, and main portal vein invasion (branch portal vein
invasion was allowed). This was done to align with the Japanese Society for Hepatology guidelines
for systemic therapy in unresectable HCC in the setting of a heavy recruitment in Asia (and Japan in
particular). Other key enrollment criteria included Child–Pugh class A liver function, ECOG PS 0 or 1,
<50% liver occupation, and the absence of portal vein invasion. The study met its primary endpoint of
OS which was shown to be non-inferior to sorafenib. Median OS duration was 13.6 months (95% CI
12.1–14.9). In addition, there was a 2.5-times increase in duration of median PFS and a 3-times increase
in objective response rate with lenvatinib. While AEs appeared comparable between the sorafenib
and lenvatinib arms, there was more hypertension but hand foot skin reaction, which often leads to
discontinuation of treatment, was less common in the lenvatinib group. Interestingly, the OS in both
arms of this trial was slightly longer than that seen with other first-line trials in HCC [14]. This may
have been due to the relatively high percentage of patients who received additional systemic and/or
non-systemic treatment after progression.
2.5. Systemic Therapy after Sorafenib
The Food and Drug Administration (FDA)-approved indications for all four approved systemic
therapies beyond front line state that they are approved for the treatment of patients “who have been
previously treated with sorafenib”. This has largely been interpreted as “subsequent line” by treaters
and experts although this issue is debatable in the absence of data on patients who have had prior
treatment with lenvatinib or immunotherapy.
Regorafenib (STIVARGA®; Bayer; Whippany, NJ, USA) is an oral tyrosine kinase inhibitor
that targets multiple protein kinases involved in tumor oncogenesis, angiogenesis, metastasis, and
immunity, including RET, VEGFR1-3, KIT, PDGFRα and β, FGFR1 and 2, RAF-1, BRAF, and CSF1R [15].
Enrolled patients had previous treatment with sorafenib at a dose of ≥400 mg/d for ≥20 of the 28
days prior to detection of progressive disease (intolerability was an exclusion) as well as BCLC
class B or C disease and Child–Pugh A liver function. The RESORCE trial showed superiority of
regorafenib vs. placebo (median OS 10.7 vs. 7.8 months; HR 0.63 (95% CI 0.50–0.79), p < 0.001) in
patients who progressed on sorafenib, the majority of whom had BCLC C disease and Child–Pugh
A liver function [16]. Furthermore, patients in this trial who received regorafenib demonstrated that
treatment with sorafenib followed by regorafenib led to a median OS since the start of sorafenib of
26.0 months [17]. As patients were pre-selected for tolerability to sorafenib, which may have allowed
them to tolerate regorafenib as well. Consequently, the efficacy of regorafenib in patients who do not
tolerate sorafenib remains unknown. As expected, the AE burden of regorafenib included hand foot
skin reaction, fatigue, and diarrhea most prominently.
Cabozantinib (CABOMETYX®; Exelixis; South San Francisco, CA, USA) is a tyrosine kinase
inhibitor that targets angiogenesis pathways with shared other agents but also inhibits MET and
AXL, which may impact components of tumor cell motility and metastasis [18,19]. The CELESTIAL
trial enrolled a broad spectrum of patients with Child–Pugh A liver function and good performance
status (ECOG 0 or 1) who had previously been treated with sorafenib [20]. Eligible patients could
have also received a variety of other systemic treatments prior to enrolling, including immunotherapy
agents. In fact, 27% had received two or more systemic therapies before starting the study. Patients on
cabozantinib had a median OS of 10.2 months compared with 8.0 months for placebo (HR 0.76 [95%
CI 0.63-0.92], p = 0.005). Pre-planned subset analyses showed that the benefit of cabozantinib was
somewhat more pronounced in patients who received only one systemic treatment (e.g., sorafenib)
prior to starting study drug. Similar to RESORCE, patients were required to have progressed on
sorafenib prior to study entry and therefore the efficacy in patients who discontinue sorafenib due to
intolerability is not known. In addition, the lack of an approved standard of care in second line at
the time the trials were conducted meant that both RESORCE and CELESTIAL were conducted with
placebo control arms. Ultimately, a trial comparing regorafenib with cabozantinib would be needed to
determine which is the optimal second-line treatment option.
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Preliminary efficacy of nivolumab (OPDIVO®; Bristol-Myers Squibb Company; Princeton, NJ,
USA) was demonstrated in the phase 1/2 CHECKMATE-040 study of sorafenib-naïve patients and
patients who progressed on sorafenib treatment [21]. Eligible patients had Child–Pugh scores of ≤7
and ECOG PS 0 or 1. PD-L1 expression was not required for entry into the trial. Notably, 61% of
patients who progressed on sorafenib who were then treated with nivolumab demonstrated disease
control, including 4% with complete responses, 18% with partial responses, and 40% with stable disease.
Disease control was reached in 66% of patients with HCV infection and 55% of patients with HBV
infection (regardless of sorafenib exposure). Median OS was not reached in this cohort of patients at the
time of publication. With regard to safety, 5% of patients required steroid treatment for autoimmune
hepatitis. The initial results were promising enough for the FDA to grant nivolumab accelerated
approval for the treatment of patients with HCC who have had prior treatment with sorafenib. The
larger, phase 3, CHECKMATE-459 trial will compare the efficacy of nivolumab vs. sorafenib in the
front-line setting, further helping to establish immunotherapy in the treatment of patients with HCC.
Additional preliminary results have been presented for pembrolizumab (KEYTRUDA®; Merck
and Co, Inc; Whitehouse Station, NJ, USA) in the KEYNOTE-224 trial [22]. Patients enrolled in this
trial had progressed on or were intolerant to sorafenib and had BCLC C or B disease with ECOG Ps 0
or 1 and Child–Pugh A liver function. This open-label phase 2 study also furthered the promise of
immuno-oncology agents in HCC in post-sorafenib patients with an objective response rate of 17%
(including one complete response). Based on these results, pembrolizumab was granted preliminary
approval for the treatment of post-sorafenib patients with HCC and further investigation in two phase
3 studies is ongoing.
The anti-VEGF antibody ramucirumab (CYRAMZA®; Eli Lilly and Company; Indianapolis, IN)
may also be prescribed in a limited population of patients with HCC based on the REACH-2 trial [23].
Patients in this trial had progressed on sorafenib or after discontinuation of sorafenib treatment and
had an AFP level ≥400 ng/mL. The results showed a median OS of 8.5 months for ramucirumab
(vs. 7.3 months for placebo).
Additional systemic therapy approaches are currently in development. The IMBrave150 study
(NCT03434379) will assess the safety and efficacy of the combination of atezolizumab + bevacizumab
relative to sorafenib in first-line HCC. The HIMALAYA study (NCT03298451) will also examine an
immunotherapy combination in first line, comparing durvalumab + tremelimumab with durvalumab
alone or sorafenib. Another ongoing study (NCT03164440) will assess the potential benefits of PD-1
inhibition with sintilimumab in combination with an anti-VEGF antibody IBI305 relative to sorafenib
in first line HCC. In addition, an early-stage study (NCT03299946) will assess the safety and feasibility
of cabozantinib + nivolumab as neoadjuvant treatment for patients with HCC. Although results have
not been reported yet, it is possible that combining approaches with known benefits (i.e., PD-1 and
VEGF inhibition) will lead to improved outcomes.
3. Multidisciplinary Care in HCC
Due to the number of different modalities utilized to treat patients with HCC, physicians with
different specialties need to be involved with developing the care plan. Diagnosis of HCC is often
made biochemically and radiographically, and the essential role of the pathologist is often to confirm
the presence of cancer using histology, especially when there is mixed histology or the possibility of an
intrahepatic cholangiocarcinoma, which has the same risk factors as HCC. Diagnostic radiologists with
a focus on abdominal imaging are integral for identifying and monitoring liver lesions as well as those
that have metastasized to other tissues.
Hepatologists are likely to be treating patients for cirrhosis or other liver diseases that preceded
the development of HCC and to have patients referred to them by other physicians including
gastroenterologists, internists, and family practitioners. Since hepatologists have an established
relationship with these patients, they are ideally placed to coordinate care, including prescribing
antiviral therapies for hepatitis and systemic therapies for HCC and monitoring and treating
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adverse events related to both systemic and locoregional treatments. In some centers, the director
of care is the hepatologist, while in others it is the medical oncologist, surgical oncologist, or
interventional radiologist.
Surgeons will perform resections or work with the multidisciplinary team to identify patients
who may benefit from the option of liver transplant or downstaging toward the goal of transplant.
Radiation oncologists may play a role in delivering EBRT or stereotactic body radiotherapy as needed.
Interventional radiologists provide input regarding efficacy, safety, and feasibility of locoregional
therapies to treat tumors in the liver as well as contribute to the determination of the ideal timing of
sequential therapies or other options required to control disease. Systemic therapy is managed by
hepatologists or medical oncologists who may also be able to offer a number of other treatment avenues
to patients, including access to clinical trials, palliative care, and survivorship support. Throughout
all stages of treatment, nurses, nurse navigators, and physician assistants provide critical support for
patients through financial counseling and adverse event management.
Each of these different disciplines comes with its own unique perspectives on how to treat patients
with this complex disease using the rapidly evolving treatment paradigm and growing list of options
that have demonstrated clinical benefits but lack data on optimal sequencing. At the same time, they
may have their own implicit biases with regard to which treatment options should be employed.
Organizing a multidisciplinary team to coordinate the inputs from these different providers can help
to maximize the benefits for patients while simultaneously countering these biases and developing
consensus where there are gaps to support evidence-based practice.
Multiple studies have shown that disease outcomes were improved when patient care was
coordinated by a multidisciplinary team (Table 2). Although quantifying the value of multidisciplinary
care is difficult because one must compare against hypothetical scenarios and the confounding effects
of improvements in treatment over time, these studies collectively showed that patients with HCC
benefited from having their treatment regimens planned by a team consisting of different specialists.
For example, patients tended to be diagnosed earlier, allowing a higher percentage to receive potentially
curative treatments [24,25]. The multidisciplinary team also ensured that a high rate of patients received
active treatment [26]. Ultimately, these benefits led to improved survival for patients with HCC across
the disease spectrum [24–27].
Implementing a multidisciplinary tumor board requires a coordinated effort among the different
stakeholders to ensure adequate representation from all the specialists who contribute to the care
of patients with unresectable HCC. Each member of the team must approach patients without any
preconceived ideas regarding treatment. Rather, decisions should be data- and consensus-driven.
Various models for multidisciplinary tumor boards exist. A weekly meeting where cases are briefly
presented to review radiology, pathology, and laboratory findings; medical history; and comorbidities
to discuss the agreed-upon care plan prior to being seen in the clinic is common at many cancer
centers. A thorough review of all old scans and all potential treatment options allows for higher patient
satisfaction and better documentation. In addition to helping to coordinate the patient’s care, this
often also minimizes the number of visits the patient needs to make to the center. Another model
for multidisciplinary care planning includes a virtual tumor board, where members are not all in
one location and may participate via the internet. Similar discussions occur, but some biases may
exist based on the dominant discussions at the site where the bulk of the discussants are present.
Presentations that are concise and have a more focused format allow for objective discussion and
review. Some centers may have algorithms to channel care/referrals, and multidisciplinary referrals
occur only when cases fall outside the set algorithms. Measuring and sharing of outcomes, improving
access to care, and removal of barriers to increase referrals to a multidisciplinary care center should be
the focus of every HCC treatment program.
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Table 2. Summary of recent studies on multidisciplinary care in unresectable HCC.
Study Design Key Findings
Charriere et al, 2017 [27]
• All patients identified for
treatment with transplant,
resection, or RFA were
prospectively enrolled
(N = 387)
• Compliance with the multidisciplinary
team’s recommendations was associated
with longer OS (HR 0.39 (95% CI
0.27–0.54), p < 0.0001)
• Factors associated with greater
compliance with the multidisciplinary
team’s recommendations included
MELD score < 10, time frame of <60
between the decision and first treatment,
platelet levels >126,000/mm3, and a
decision for resection or RFA
Serper et al, 2017 [26]
• Review of Veterans
Administration clinical data
repository (N = 3988)
• Evaluation by >1 specialist was
significantly associated with a higher
likelihood of receiving active therapy
(OR 1.60 ([95% CI 1.15–1.21))
• Presence of a multidisciplinary team in
the provider facility was associated with
longer OS (HR 0.83 (95% CI 0.77–0.90))
Yopp et al, 2014 [25]
• Patients diagnosed before and
after the establishment of a
multidisciplinary clinic were
retrospectively evaluated
(N = 355)
• Patients in the multidisciplinary clinic
were diagnosed at an earlier stage and
presented with fewer symptoms and
better ECOG PS than those treated
before the clinic was established
• Potentially curative treatment was more
likely to be given in the
multidisciplinary clinic, with a
significantly longer median OS than
those treated before the clinic was
established (13.2 months vs. 4.8 months
(p = 0.005)
Chang et al, 2008 [24]
• Survival of patients treated
before and after the
implementation of a
multidisciplinary team
was compared
• N = 121 treated by the
multidisciplinary team
• Rate of patients referred to surgical
services doubled after implementing the
multidisciplinary tumor board,
significantly increasing the number of
patients treated in the early stages of
the disease
• Survival rates were significantly higher
in patients treated by the
multidisciplinary team
ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; MELD, Model for End-Stage
Liver Disease; OR, odds ratio; OS, overall survival; RFA, radiofrequency ablation.
4. Conclusions: Moving into the Future of Treating Patients with Unresectable HCC
The treatment paradigm for patients with unresectable HCC is expected to change rapidly in
the next several years. For over a decade, the treatment options for these patients have been limited
to locoregional therapies, sorafenib, and best supportive care, which subsequently set patterns of
referral. However, while new studies have provided more evidence-based choices in the ways this
population can be treated, they also bring to light evidence gaps and new possibilities. Consequently,
a more thoughtful approach to each patient is needed. Now more than ever, a multidisciplinary team
is needed to improve the care of patients with unresectable HCC.
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Many institutions are developing pathways in an attempt to standardize the care of their patients.
However, patients with unresectable HCC are an extremely heterogeneous population, and therefore,
developing one pathway that applies to all patients is extremely challenging. A cross-functional
approach to each patient provides the opportunity to utilize the expertise of the different disciplines
involved in the care of these patients where no standardized approaches are available.
In addition, health care reform in the United States has placed a greater emphasis on documenting
and managing comorbidities. As new treatments improve survival, the practice of oncology will see a
rise in the number and severity of comorbidities in patients with unresectable HCC. In addition to these
comorbidities, physicians managing these patients often must also manage multiple complications
associated with underlying liver disease and (in some patients) previous treatments for HBV or HCV.
Palliative care due to the presence of metastatic disease is also likely to be needed. Consequently,
patients with unresectable HCC will need to be cared for by many different specialists. Instituting a
multidisciplinary team to address all of these different needs should help to insure the highest quality
of care, while at the same time controlling costs and maintaining patient satisfaction.
The rapidly changing landscape in HCC will also be impacted by new studies assessing the
benefits of locoregional therapy on survival and a number of positive studies that were recently
reported and new drug approvals expected in the coming year. Consequently, multidisciplinary
discussions will become even more essential to implementing evidence-based practice decisions that
require a reassessment of local therapies and when options based on non-inferiority become available
with no data on optimal treatment options following progression on those agents, a knowledge gap that
has been noted in the updated BCLC guidelines [28]. Furthermore, several tyrosine kinase inhibitors
studied after progression on sorafenib that were found to be superior in prolonging survival when
compared to placebo are expected to become available in the coming year but their efficacy relative to
each other has not been assessed and their efficacy without prior sorafenib exposure is not known.
As more options become available and patients begin to be referred for systemic treatment earlier,
defining progression will be critical. Optimal criteria to change treatment based on the type of therapy
the patient is receiving (e.g., immune checkpoint inhibitors or tyrosine kinase inhibitors) will need
careful consideration, as maximizing duration and tolerability of each therapy will be key to increasing
survival in these patients. A cross-functional approach with a multidisciplinary team should help to
define these criteria.
The management of hypertension, variceal surveillance, and hospitalizations that can occur during
prolonged therapy and immunotherapy may also require oncologists to oversee care delivered by multiple
providers. In addition, there have not been definitive studies done on impact of treating HCV in patients
with advanced HCC; such treatments are done on a case-by-case basis and require multidisciplinary care.
Maintaining a multidisciplinary team to treat these patients ensures that their care will involve
the use of the most appropriate tools at the most appropriate times. Instituting just such a team of
specialists from key disciplines will facilitate the incorporation of multiple points of view and treatment
techniques that are most beneficial to patients with HCC. This multifaceted approach should provide
the best possible outcomes for this patient population. This article is meant to review outcomes,
options, and toxicity to serve as a resource for all those disciplines.
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